[1]郭孟子,李紫航,陈艺璇,等.“三医”协同视角下国谈药“双通道”高质量发展研究[J].卫生经济研究,2024,41(08):4-7.
　GUO Mengzi,LI Zihang,CHEN Yixuan,et al.Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy[J].Journal Press of Health Economics Research,2024,41(08):4-7.
点击复制

“三医”协同视角下国谈药“双通道”高质量发展研究

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年08期
页码:
4-7
栏目:
专题研究
出版日期:
2024-08-01

文章信息/Info

Title:
Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy
作者:
郭孟子1; 李紫航1; 陈艺璇1; 陈湘婉1; 程 智1; 汤质如1
1.安徽医科大学卫生管理学院，安徽 合肥 230032
Author(s):
GUO Mengzi;  LI Zihang;  CHEN Yixuan;  CHEN Xiangwan;  CHENG Zhi;  TANG Zhiru
School of Health Management, Anhui Medical University, Hefei Anhui 230032, China
关键词:
“三医”协同; 国家谈判药品; 双通道; 高质量发展
Keywords:
"three medical" synergy;  national negotiated drugs;  double channel;  high-quality development
分类号:
F840.684；C913.7
文献标志码:
A
摘要:
目的：从“三医”协同视角分析国谈药“双通道”的利益相关者关系，提出促进国谈药“双通道”高质量发展的策略。方法：采用政策与文献分析法、专家咨询法，对国谈药“双通道”政策的执行情况、存在的问题以及利益相关者关系进行分析。结果：国谈药“双通道”政策实施以来，配备国谈药的医药机构数从15.47万家增至20.9万家，其中定点医疗机构数和定点零售药店数分别达到5.4万家和15.5万家；政府担任主导角色，定点医疗机构、定点零售药店及制药企业等均为利益相关者，面临着各自的激励和风险因素。结论：医保部门提升精细化管理水平，定点医疗机构提高配备使用“双通道”药品的积极性，定点零售药店提升药品服务能力，制药企业提高核心竞争力，构建“三医”协同治理格局，推动国谈药“双通道”高质量持续发展。
Abstract:
Objective To analyze the stakeholder relationship of the "dual channel" of national negotiated drugs from the perspective of "three medical" synergy, and to put forward the strategies to promote high-quality development of the "dual channel" of national negotiated drugs. Methods Through policy and literature analysis and expert consultation, the implementation of the "dual channel" policy, existing problems and stakeholder relations were analyzed. Results Since the implementation of the "dual channel" policy of national negotiated drugs, the number of medical institutions equipped with national negotiated drugs had increased from 154 700 to 209 000, of which the number of designated medical institutions and designated retail pharmacies reached 54 000 and 155 000, respectively. The government played a leading role, and designated medical institutions, designated retail pharmacies and pharmaceutical companies were all stakeholders, facing their own incentives and risk factors. Conclusion The health insurance department should improve the level of detailed management, designated medical institutions should increase the motivation to equip and use "dual channel" drugs, designated retail pharmacies should improve the ability to provide drugs services, and pharmaceutical companies should improve their core competitiveness, so as to build a synergistic governance pattern of the "three medical" and promote high-quality development of the "dual channel" of national negotiated drugs.

参考文献/References:

[1] 郭丽婷，赵树梅，张方东，等.“双通道”政策助力农村药品市场健康发展的对策研究[J].农业经济，2023（09）：142-144.
[2] 胡清元.芜湖市药品“双通道”政策执行问题及优化研究[D].芜湖：安徽工程大学，2023.
[3] 浙江省医疗保障局.浙江省纳入“双通道”管理药品名单（2023年3月1日起）[EB/OL].（2023-03-01）[2023-10-31].http://ybj.zj.gov.cn/art/2023/3/1/art_1229225636_5074133.html.
[4] 广东省医疗保障局.关于印发“双通道”管理药品范围（2023年）的通知[EB/OL].（2023-02-22）[2023-10-31].http://hsa.gd.gov.cn/gab/ bmwj/content/post_4098840.html.
[5] 安徽省医疗保障局,安徽省卫生健康委.关于建立完善全省国家医保谈判药品“双通道”管理机制的通知（皖医保秘〔2021〕58号）[EB/OL].（2021-06-03）[2023-10-31].http://ybj.ah.gov.cn/public/7071/146111521.html.
[6] 福建省医疗保障局.关于建立国家医保谈判药品“双通道”管理机制的通知（闽医保〔2021〕78号）[EB/OL].（2021-09-02）[2023-10-31].http://ybj.fujian.gov.cn/zfxxgkzl/fdzdgknr/zcwj/202109/t2021 0902_5680184.htm.
[7] 山东省医疗保障局.关于做好全省2023年城乡居民基本医疗保障工作的通知（鲁医保发〔2023〕36号）[EB/OL].（2023-08-18）[2023-10-31].http://ybj.shandong.gov.cn/art/2023/8/18/art_65415_103072 01.html.
[8] 安徽省医疗保障局.关于咨询“双通道”等相关问题[EB/OL].（2022-06-17）[2023-10-31].https://ybj.ah.gov.cn/ztzl/ybsy/14671 12851.html.
[9] 山东省医疗保障局.关于进一步完善国家医保谈判药品“双通道”管理机制有关事项的通知（鲁医保函〔2022〕27号）[EB/OL].（2022-05-19）[2023-10-31].http://ybj.shandong.gov.cn/art/2022/5/19/art_113614_10293942.html.
[10] 四川省医疗保障局，四川省卫生健康委员会.转发《国家医保局 国家卫生健康委关于建立完善国家医保谈判药品“双通道”管理机制的指导意见》的通知（川医保办发〔2021〕27号）[EB/OL].（2021-11-12）[2023-10-31].http://ylbzj.sc.gov.cn/scsybj/nc010416/2021/11/12/9953b55184ce4b51b504deb3b3705656cc.shtml.
[11] 吉林省医疗保障局.关于加强国家医保谈判药品配备使用完善“双通道药品”管理机制的通知（吉医保联〔2021〕26号）[EB/OL].（2021-11-23）[2023-10-31].http://xxgk.jl.gov.cn/zsjg/fgw/xxgkmlqy/202111/t20211123_8297201.html.
[12] 福建省医疗保障局，福建省卫生健康委员会.关于建立国家医保谈判药品“双通道”管理机制的通知（闽医保〔2021〕78号）[EB/OL].（2021-08-27）[2023-10-31].http://ybj.fujian.gov.cn/zfxxgkzl/fdzdgknr/zcwj/202109/t20210902_5680184.htm.
[13] 上海市医疗保障局.关于落实国家医保谈判药品“双通道”管理机制的通知（沪医保医管发〔2021〕40号）[EB/OL].（2021-11-27）[2023-10-31].http://ybj.sh.gov.cn/qtwj/20211130/b4e8016fe521 45e384b81159cce7fd13.html.
[14] 浙江省医疗保障局.关于落实国家医保谈判药品“双通道”管理机制的通知（浙医保联发〔2021〕24号）[EB/OL].（2021-11-02）[2023-10-31].http://ybj.zj.gov.cn/art/2021/11/2/art_1229113 757_2371819.html.
[15] 郭子凡，陈大鹏，王浩宇.基于Spring Boot框架的医院“双通道”处方流转系统设计与实现[J].医疗卫生装备，2023，44（03）：39-44.
[16] 朱文静，许龙，温瑞睿，等.新形势下DTP药房对执业药师专业药学服务需求探讨[J].中国药事，2023，37（05）：535-539.
[17] 孙雅群，宋燕.山东省国家医保谈判药品“双通道”管理政策比较研究[J].卫生软科学，2023，37（10）：13-16.

相似文献/References:

[1]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(08):42.
[2]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(08):17.
[3]严 晶,张 燕.DRG付费下国家谈判药品政策落地的实践[J].卫生经济研究,2021,38(12):20.
　YAN Jing,ZHANG Yan.Practice of National Negotiated Drug Policy Implementation under DRG Payment[J].Journal Press of Health Economics Research,2021,38(08):20.
[4]张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15.
　ZHANG Yu-wan,TAN Zai-xiang,LU Ya-juan.Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs——Taking S City as An Example[J].Journal Press of Health Economics Research,2022,39(08):15.
[5]王宁锋,李雪竹,张 慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16.
　WANG Ningfeng,LI Xuezhu,ZHANG Hui.Study on One-way Payment Policy for the State-negotiated Drugs[J].Journal Press of Health Economics Research,2024,41(08):16.
[6]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(08):8.
[7]付馨宁,董洁仪,唐宁婧,等.国家谈判药品落地影响因素研究 ——基于多维尺度分析和社会网络分析[J].卫生经济研究,2025,42(11):62.
　FU Xinning,DONG Jieyi,TANG Ningjing,et al.Study on the Influencing Factors of the Implementation of National Negotiated Drugs ——Based on Multidimensional Scaling and Social Network Analysis[J].Journal Press of Health Economics Research,2025,42(08):62.
[8]赵 云,黄晓静,温宗良.深化基层医改路径研究[J].卫生经济研究,2026,43(01):37.
　ZHAO Yun,HUANG Xiaojing,WEN Zongliang.Advancing the Pathway of Primary Care Reform in China[J].Journal Press of Health Economics Research,2026,43(08):37.
[9]王 琪,杜启霞,乔学斌,等.整体智治视角下数字化赋能“三医”协同发展和治理研究 ——基于南京“医保高铁”案例分析[J].卫生经济研究,2026,43(02):21.
　WANG Qi,DU Qixia,QIAO Xuebin,et al.Study on the Digital Empowerment for the Coordinated Development and Governance of Medical Services, Medical Securityand Pharmaceutical Industry from the Perspective of Holistic Intelligent Governance——Based on a Case Study of Nanjing’s "Medical Insurance High-Speed Railway"[J].Journal Press of Health Economics Research,2026,43(08):21.
[10]吴 珍,陈星宇,胡琳琳.药品领域“三医”协同治理困境与优化路径研究[J].卫生经济研究,2026,43(04):1.
　WU Zhen,CHEN Xingyu,HU Linlin.Collaborative Governance Dilemmas and Optimization Strategies for "Three Medicals" Synergy in the Pharmaceutical Sector[J].Journal Press of Health Economics Research,2026,43(08):1.

更新日期/Last Update: 2024-08-01